VEDOLIZUMAB

vedolizumab 108 mg/0.68 mL injection, 2 x 0.68 mL pen devices

VEDOLIZUMAB (12654B)

vedolizumab 108 mg/0.68 mL injection, 2 x 0.68 mL pen devices
12654B
Body System:
Manner of administration:Injection
General Schedule
Authority Required

Restriction

Indication: Severe Crohn disease
Treatment phase: Transitioning from non-PBS-subsidised therapy that was commenced as a paediatric patient

Restriction

Indication: Severe Crohn disease
Treatment phase: Continuing treatment
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 2 # of repeats: 5 DPMQ: $1,663.81 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Entyvio